Indomethacin, a Non-steroidal Anti-inflammatory Drug, Induces Skin Dryness via PPARγ in Mice

Biol Pharm Bull. 2022 Jan 1;45(1):77-85. doi: 10.1248/bpb.b21-00532. Epub 2021 Oct 30.

Abstract

Cyclooxygenase (COX)-1-selective inhibitors have side effects such as itching and dryness of the skin. In this study, the degree of skin dryness and the onset mechanism of this condition were investigated by comparing the effects of three non-steroidal anti-inflammatory drugs (NSAIDs) in mice. Mice were orally administered either indomethacin, loxoprofen sodium, or celecoxib (n = 5 per group) once daily for four consecutive days, and blood samples as well as skin and jejunal tissues were isolated on day 5. In the mice treated with indomethacin, transepidermal water loss was significantly increased, and dry skin was observed. In addition, the expression of matrix metalloproteinase (MMP)-I, mast cells, CD163, CD23, CD21, histamine, and peroxisome proliferation-activated receptor (PPAR)γ in the skin and jejunum was increased, and the blood levels of interleukin-10 and immunoglobulin E were also increased. In contrast, the expression of collagen type I in the skin was decreased. These results show that indomethacin activates PPARγ in the skin and jejunum, changes the polarity of macrophages, increases the secretion of MMP-1 from mast cells, and decomposes collagen type I, leading to dry skin.

Keywords: dry skin; indomethacin; macrophage; mast cell; peroxisome proliferation-activated receptor γ.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Celecoxib
  • Cyclooxygenase 2
  • Cyclooxygenase Inhibitors / pharmacology
  • Indomethacin* / pharmacology
  • Mice
  • PPAR gamma*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • PPAR gamma
  • Cyclooxygenase 2
  • Celecoxib
  • Indomethacin